Helius Medical Technologies’ (HSDT) “Hold” Rating Reiterated at Maxim Group

Maxim Group reiterated their hold rating on shares of Helius Medical Technologies (NASDAQ:HSDT) in a report released on Wednesday morning, Benzinga reports.

Helius Medical Technologies Trading Up 47.0 %

Shares of HSDT stock opened at $0.55 on Wednesday. Helius Medical Technologies has a twelve month low of $0.37 and a twelve month high of $9.50. The stock has a market cap of $1.63 million, a P/E ratio of -0.04 and a beta of 1.60. The stock has a 50 day moving average of $0.70 and a 200 day moving average of $1.67.

Helius Medical Technologies (NASDAQ:HSDT) last posted its earnings results on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.14). The firm had revenue of $0.18 million during the quarter. Helius Medical Technologies had a negative net margin of 1,487.54% and a negative return on equity of 258.06%. During the same period in the prior year, the company posted ($3.00) EPS.

Hedge Funds Weigh In On Helius Medical Technologies

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC bought a new position in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned 4.39% of Helius Medical Technologies at the end of the most recent reporting period. 18.63% of the stock is owned by institutional investors and hedge funds.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.